Adaptive Biotechnologies vs Aurinia Pharmaceuticals
Adaptive Biotechnologies and Aurinia Pharmaceuticals are similar in size: $277m and $283m of revenue in their latest fiscal years. Adaptive Biotechnologies grew faster (54.8% against 20.4%). Aurinia Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 101.5% against -21.5%. Aurinia Pharmaceuticals carries less debt relative to equity (0.0% against 60.0%).
| Latest fiscal year | Adaptive BiotechnologiesADPT, 2025 | Aurinia PharmaceuticalsAUPH, 2025 |
|---|---|---|
| Revenue | $277m | $283m |
| Revenue growth | 54.8% | 20.4% |
| Net income | −$59.5m | $287m |
| Operating margin | -20.6% | 37.1% |
| Net margin | -21.5% | 101.5% |
| Return on equity | -28.2% | 59.9% |
| Free cash flow | −$48.9m | — |
| Cash | $70.5m | $80.2m |
| Total debt | $131m | $0 |
| Debt to equity | 60.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $98.2m |
| Employees | 624 | 128 |
| Market value | $4.10bn | $2.23bn |
| Price vs our value range | — | Below our value range |
| Moat score | 24 (Weak) | 32 (Weak) |
| Insider trades, 12 months | 0 buys, 168 sales | 11 buys, 2 sales |